Syner-Med Improves Sales Execution with ³Ô¹Ï±¬ÁÏ OpenData
³Ô¹Ï±¬ÁÏ delivers the right data and insights for UK pharmaceutical company to drive tailored interactions with customers
PLEASANTON, CA ¡ª Dec. 7, 2017 ¡ª ³Ô¹Ï±¬ÁÏ Systems today announced that , a fast-growing U.K. pharmaceutical company, is using ³Ô¹Ï±¬ÁÏ OpenData and ³Ô¹Ï±¬ÁÏ CRM to empower field teams with accurate customer data and drive smarter engagement with customers. ³Ô¹Ï±¬ÁÏ OpenData and ³Ô¹Ï±¬ÁÏ CRM are part of ³Ô¹Ï±¬ÁÏ Commercial Cloud, a suite of applications that Syner-Med is adopting to establish a foundation for their commercial operations as the company launches more new products over the next two years.
¡°³Ô¹Ï±¬ÁÏ delivers quality customer data, right in CRM, to improve our sales execution and create more valued interactions with our customers,¡± said Dipak Bhatti, managing director of Syner-Med. ¡°We now have the foundation in place for a consistent commercial approach and to support our future growth.¡±
Syner-Med¡¯s previous data sources limited their ability to track customer activities and placed a heavy administrative burden on field reps to maintain accurate customer data. Data change requests could often take weeks, so sales and marketing teams worked from outdated information and had a fragmented view of customer engagement across the company.
³Ô¹Ï±¬ÁÏ brings together complete customer data and multichannel engagement to help Syner-Med achieve greater commercial effectiveness. ³Ô¹Ï±¬ÁÏ OpenData keeps data current using a combination of data science and ³Ô¹Ï±¬ÁÏ data stewards that can make change requests within two hours versus the industry average of 10 days or more. As a result, field teams have an accurate view of their customers in ³Ô¹Ï±¬ÁÏ CRM to deliver smarter, more informed interactions.
¡°Quality customer data is key to successful commercial execution and increased sales and marketing efficiency,¡± said Rebecca Silver, global vice president of ³Ô¹Ï±¬ÁÏ OpenData. ¡°With accurate data in ³Ô¹Ï±¬ÁÏ CRM, Syner-Med field and medical teams can drive more value-based conversations with their customers.¡±
³Ô¹Ï±¬ÁÏ OpenData delivers access to approximately 16 million healthcare professionals (HCPs) and their healthcare organizations (HCOs) spanning 42 countries. ³Ô¹Ï±¬ÁÏ OpenData can help customers achieve greater commercial success and improve sales execution and customer engagement.
Looking ahead, Syner-Med plans to adopt additional ³Ô¹Ï±¬ÁÏ Commercial Cloud applications, including ³Ô¹Ï±¬ÁÏ Vault PromoMats to combine creation, review, and distribution of commercial content with digital asset management; ³Ô¹Ï±¬ÁÏ Align to perform fast, accurate territory alignments; ³Ô¹Ï±¬ÁÏ CRM Approved Email and ³Ô¹Ï±¬ÁÏ CRM Engage to extend reach through digital channels such as email, online meetings, and virtual events; and ³Ô¹Ï±¬ÁÏ CLM to tailor calls and make sales materials easy to access and share.
³Ô¹Ï±¬ÁÏ Commercial Cloud is the life sciences industry¡¯s trusted foundation for intelligent customer engagement. To learn more about how ³Ô¹Ï±¬ÁÏ Commercial Cloud is helping life sciences companies place their customers at the center of their commercial strategies, visit veeva.com/CommercialCloud.
Additional Information
For more on ³Ô¹Ï±¬ÁÏ OpenData, visit: veeva.com/OpenData
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:
Like ³Ô¹Ï±¬ÁÏ on Facebook:
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ has more than 600 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-Q for the period ended October 31, 2017. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.
###
Contact:
³Ô¹Ï±¬ÁÏ Systems
pr@veeva.com